tiprankstipranks
Advertisement
Advertisement

AU:ARX Stock Latest News

Aroa Biosurgery Seeks ASX Quotation for New Share Issue
Company AnnouncementsAroa Biosurgery Seeks ASX Quotation for New Share Issue
15d ago
ARX
Aroa Biosurgery Flags Lapse and Expiry of Equity Incentives, Trimming Potential Dilution
PremiumCompany Announcements
Aroa Biosurgery Flags Lapse and Expiry of Equity Incentives, Trimming Potential Dilution
17d ago
ARX
Aroa Biosurgery’s Symphony Trial Hits Key Endpoint in Diabetic Foot Ulcers
PremiumCompany Announcements
Aroa Biosurgery’s Symphony Trial Hits Key Endpoint in Diabetic Foot Ulcers
27d ago
ARX
Aroa Biosurgery to Release Small Tranche of Escrowed Director Shares
PremiumCompany Announcements
Aroa Biosurgery to Release Small Tranche of Escrowed Director Shares
1M ago
ARX
Aroa Biosurgery Targets Trauma Wound Market With New Phase 4 Myriad–NPWT Trial
PremiumCompany Announcements
Aroa Biosurgery Targets Trauma Wound Market With New Phase 4 Myriad–NPWT Trial
3M ago
ARX
Aroa Biosurgery Seeks ASX Quotation for New Shares Issued Under Employee Incentive Scheme
PremiumCompany AnnouncementsAroa Biosurgery Seeks ASX Quotation for New Shares Issued Under Employee Incentive Scheme
3M ago
ARX
Aroa Biosurgery Issues Investor-Focused February 2026 Business Update
Premium
Company Announcements
Aroa Biosurgery Issues Investor-Focused February 2026 Business Update
3M ago
ARX
Aroa Biosurgery Poised to Gain From US Reimbursement Shift as New Data Backs Myriad
Premium
Company Announcements
Aroa Biosurgery Poised to Gain From US Reimbursement Shift as New Data Backs Myriad
3M ago
ARX
Aroa Biosurgery’s Symphony Trial Completion: What Diabetic Ulcer Data Could Mean for AU:ARX
PremiumCompany Announcements
Aroa Biosurgery’s Symphony Trial Completion: What Diabetic Ulcer Data Could Mean for AU:ARX
3M ago
ARX
Aroa Biosurgery Schedules Investor Webinar to Detail Symphony Reimbursement and Clinical Data
PremiumCompany Announcements
Aroa Biosurgery Schedules Investor Webinar to Detail Symphony Reimbursement and Clinical Data
3M ago
ARX
Aroa Biosurgery Study Backs Efficacy and Cost Edge of Myriad Trauma Scaffold
PremiumCompany Announcements
Aroa Biosurgery Study Backs Efficacy and Cost Edge of Myriad Trauma Scaffold
3M ago
ARX
Aroa Biosurgery Options Lapse Following Unmet Vesting Conditions
PremiumCompany Announcements
Aroa Biosurgery Options Lapse Following Unmet Vesting Conditions
4M ago
ARX
Aroa’s Symphony Wins Extended US Medicare Access as CMS Tightens Skin Substitute Rules
PremiumCompany AnnouncementsAroa’s Symphony Wins Extended US Medicare Access as CMS Tightens Skin Substitute Rules
4M ago
ARX
Aroa Biosurgery Ltd Reports Half-Year 2026 Results
Premium
Company Announcements
Aroa Biosurgery Ltd Reports Half-Year 2026 Results
5M ago
ARX
Aroa Biosurgery Achieves Strong Revenue Growth and Financial Stability in H1 FY26
Premium
Company Announcements
Aroa Biosurgery Achieves Strong Revenue Growth and Financial Stability in H1 FY26
5M ago
ARX
Aroa Biosurgery Reports Improved Financial Performance Amid Sales Growth
PremiumCompany Announcements
Aroa Biosurgery Reports Improved Financial Performance Amid Sales Growth
5M ago
ARX
Aroa Biosurgery Issues Unquoted Equity Securities for Employee Incentive
PremiumCompany Announcements
Aroa Biosurgery Issues Unquoted Equity Securities for Employee Incentive
5M ago
ARX
Aroa Biosurgery to Host Investor Event on H1 FY26 Results and Outlook
PremiumCompany Announcements
Aroa Biosurgery to Host Investor Event on H1 FY26 Results and Outlook
6M ago
ARX
Aroa Biosurgery Announces Director Departure and Securities Update
PremiumCompany Announcements
Aroa Biosurgery Announces Director Departure and Securities Update
6M ago
ARX
Aroa Biosurgery Announces Board Changes with New Appointment and Retirement
PremiumCompany AnnouncementsAroa Biosurgery Announces Board Changes with New Appointment and Retirement
6M ago
ARX
Aroa Biosurgery’s Symphony™: A New Hope for Diabetic Foot Ulcers?
Premium
Company Announcements
Aroa Biosurgery’s Symphony™: A New Hope for Diabetic Foot Ulcers?
6M ago
ARX
Aroa Biosurgery’s Myriad™ Study: A Potential Game-Changer in Soft Tissue Reconstruction
Premium
Company Announcements
Aroa Biosurgery’s Myriad™ Study: A Potential Game-Changer in Soft Tissue Reconstruction
6M ago
ARX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >